{"id":31747,"date":"2025-05-10T06:47:22","date_gmt":"2025-05-10T04:47:22","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/05\/10\/harnessing-endogenous-anti-glycan-antibodies-using-a-novel-bifunctional-immunotherapy-to-treat-gram-negative-bacterial-infections\/"},"modified":"2025-05-10T06:47:22","modified_gmt":"2025-05-10T04:47:22","slug":"harnessing-endogenous-anti-glycan-antibodies-using-a-novel-bifunctional-immunotherapy-to-treat-gram-negative-bacterial-infections","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/05\/10\/harnessing-endogenous-anti-glycan-antibodies-using-a-novel-bifunctional-immunotherapy-to-treat-gram-negative-bacterial-infections\/","title":{"rendered":"Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2025 May 9:vkaf055. doi: 10.1093\/jimmun\/vkaf055. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>The current array of traditional antibacterial agents targeting Gram-negative infections are failing to meet the clinical need. Here we present a novel, bifunctional immunotherapy (CTX-09) with the ability to harness endogenous anti-galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (anti-\u03b1Gal) antibodies to drive immune-mediated clearance of Gram-negative bacteria. In addition, CTX-09 has direct-acting broad-spectrum bactericidal activity equivalent to colistin and meropenem against 1952 Gram-negative clinical isolates. In vitro, CTX-09 demonstrated immune-mediated efficacy through recruitment of anti-\u03b1Gal antibodies and engagement of antibody effector mechanisms that enhanced bacterial clearance at sub-bactericidal concentrations. In vivo, at sub-bactericidal doses, CTX-09 demonstrated anti-\u03b1Gal antibody driven clearance of susceptible and multidrug-resistant (MDR) strains. In the presence of anti-\u03b1Gal antibody, bacterial burden was reduced by &gt;99.9% (3-log10) in neutropenic mouse thigh and pneumonia infection models. This data suggest that CTX-09 or other antibody-recruiting molecules have potential to address the urgent clinical need of patients with gram-negative infections using a novel immunotherapeutic mechanism.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40344777\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20250510004715&amp;v=2.18.0.post9+e462414\">40344777<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkaf055\">10.1093\/jimmun\/vkaf055<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2025 May 9:vkaf055. doi: 10.1093\/jimmun\/vkaf055. Online ahead of print. ABSTRACT The current array of traditional antibacterial agents targeting Gram-negative infections are failing to meet the clinical need. Here we present a novel, bifunctional immunotherapy (CTX-09) with the ability to harness endogenous anti-galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (anti-\u03b1Gal) antibodies to drive immune-mediated clearance of Gram-negative bacteria. In addition, &#8230; <a title=\"Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/05\/10\/harnessing-endogenous-anti-glycan-antibodies-using-a-novel-bifunctional-immunotherapy-to-treat-gram-negative-bacterial-infections\/\" aria-label=\"Read more about Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-31747","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/31747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=31747"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/31747\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=31747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=31747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=31747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}